-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $35

Benzinga·03/03/2026 18:00:47
Listen to the news
Citigroup analyst Samantha Semenkow maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $33 to $35.